华纳药厂688799 69.00分综合得分 较强 时间: 2025年5月23日星期五 趋势方向 主力成本分析 49.51 元 当日主力成本 46.66 元 5日主力成本 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 44.24 元 20日主力成本 41.42 元 短期支撑位 48.61 中期压力位 0 次 技术面分析 47.99 短期压力位 43.21 2025年05月23日的资金流向数据方面 41.49 中期支撑位 | 主力资金净流入4478.66万元 | | --- | | 占总成交额15% | | 超大单净流入2486.40万元 | | 大单净流入1992.26万元 | | 散户资金净流出13.26万 | 关联行业/概念板块 化学制药 1.63%、婴童概念 -1.03%、病毒防治 0.13%、流感 0.77%等 股价突破短期压力位，短线有望走强； 股价突破中期压力位，中线有望走强 K线形态 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为 ...

Warner Pharmaceuticals Conference Call Summary Company Overview - Warner Pharmaceuticals reported a net profit decline of 20% year-on-year to 164 million yuan in 2024, primarily due to a more than 50% increase in R&D expenses [2][3] - In Q1 2025, the company generated revenue of 336 million yuan, with 257 million yuan from formulation business and 76 million yuan from API business [2][3] Financial Performance - Total revenue for 2024 was 1.413 billion yuan, with formulation business at 1.052 billion yuan (down approximately 5%) and API business at 346 million yuan (up approximately 20%) [3] - R&D expenses for 2024 were around 150 million yuan, expected to increase to between 150 million and 200 million yuan in 2025 [4][15] R&D and Product Development - The company has adopted a cluster and integrated raw material formulation strategy for generics, obtaining 9 formulation approvals and 11 API Class A approvals since 2024 [2][6] - Ongoing clinical trials include: - ZG001 for depression in Phase II - ZG002 for autoimmune diseases in Phase I - Front-clear granules preparing for Phase III, which offers advantages over endangered animal materials [2][4][6][7] - Development of a small molecule drug for moderate to severe psoriasis is in Phase I, aiming to be a Best-in-Class product [4][13] Manufacturing and Capacity Expansion - The existing plant is operating at full capacity, prompting the establishment of a new API base covering 230 acres to support current and future production needs [2][5] Market Strategy and Regulatory Compliance - The company is actively responding to changes in centralized procurement policies, with over 60% of existing products entering national procurement and alliance procurement [21] - New policies from the National Medical Insurance Bureau are perceived as slightly more lenient, potentially benefiting companies in adapting to the market [22] Future Growth Plans - Warner Pharmaceuticals aims to stabilize cash flow through its pharmaceutical platform while expanding its generics and innovative drug businesses [23][26] - The company is exploring investment opportunities in innovative drugs, particularly through the ZhiGen platform focused on small molecule drug development [23][24] - The Tianji Rare Project is positioned in the endangered species protection sector, with supportive policies emerging since 2023 [25] Conclusion - Warner Pharmaceuticals is navigating a challenging market environment with strategic investments in R&D and capacity expansion, while also adapting to regulatory changes to ensure future growth and sustainability [23][26]

司"）2025 年 5 月 12 日的2024年年度股东大会审议通过。 证券代码：688799 证券简称：华纳药厂 公告编号：2025-054 湖南华纳大药厂股份有限公司2024年年度权益分派 实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 新增无限售条件流 股权登记日 除权（息）日 现金红利发放日 通股份上市日 一、 通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经湖南华纳大药厂股份有限公司（以下简称"公 二、 分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配及转增股本以方案实施前的公司总股本93,800,000股为基数，每 股派发现金红利0.60元（含税），以资本公积金向全体股东每股转增0.40股，共计 派发现金红利56,280,000.00元，转增37,520,000股，本次分配后总 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-054 湖南华纳大药厂股份有限公司2024年年度权益分派 实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/5/28 | 2025/5/29 | 2025/5/29 | 2025/5/29 | 一、 通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本以方案实施前的公司总股本93,800,000股为基数，每 股派发现金红利0.60元（含税），以资本公积金向全体股东每股转增0.40股，共计 派发现金红利56,280,000.00元，转增37,520,000股，本次分配后总股本为131,320,000 股。 三、 相关日期 | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | ...

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-053 湖南华纳大药厂股份有限公司 自愿披露关于子公司原料药获得上市申请批准通知 书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南 华纳大药厂手性药物有限公司收到国家药品监督管理局签发的乙酰半胱氨酸《化 学原料药上市申请批准通知书》（通知书编号：2025YS00388），并在国家药品监 督管理局药品审评中心（CDE）"原料药、药用辅料和药包材登记信息公示"平 台公示。具体情况如下： 3、申请事项：境内生产化学原料药上市申请 4、包装规格：5kg/桶，10kg/桶，25kg/桶 一、原料药登记信息 1、化学原料药名称：乙酰半胱氨酸 5、生产企业：湖南华纳大药厂手性药物有限公司 6、生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道 139 号 2、登记号：Y20230001045 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注 ...

证券研究报告 医药生物 | 化学制药 非金融|首次覆盖报告 hyzqdatemark 2025 年 05 月 21 日 | 2025 | | 年 | 05 | 月 20 | 日 | | | | | | | | | | | | 基本数据 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | 44.75 | | | | | | | | | | | | | | | 低 | | | | | | 年 | | | 高 | / | 最 | | 一 | | 最 | 内 | | | | 总市值（百万元） 4,197.55 | 流通市值（百万元） 4,197.55 | | | | 93.80 24.13 19.58 | （元） | 资产负债率（%） | 资料来源：聚源数据 | | | | 56.00/32.88 | | 总股本（百万股） | | | | 每股净资产（元/股） | 华纳药厂(688799.SH) ...

本报记者 何文英 长沙望城铜官工业片区内，湖南华纳大药厂手性药物有限公司的数个生产车间满负荷运转。即便如此， 市场需求的持续攀升仍在叩击公司的产能天花板。 距此数里之遥，占地百亩的绿色智造基地建设现场热火朝天。作为湖南华纳大药厂股份有限公司（以下 简称"华纳药厂"）战略布局的重要落子，年产3000吨高端原料药及中间体项目自开工以来建设进度势如 破竹，短短半年即将实现三大车间主体封顶。据悉，这座现代化医药生产基地预计2026年5月份迎来首 期投产，届时将为企业锻造更具韧性的产业链条，构筑原料药领域的核心竞争力。 近日，《证券日报》记者通过深度调研了解到，以高端原料药为突破口，从品种和市场双重维度描绘发 展蓝图，华纳药厂正在探索一条破局行业内卷的生物医药企业高质量发展路径。 记者在新基地现场看到，400余名建设者挥汗如雨，在楼宇之巅与地基深处展开冲刺。项目工程师管跃 平向《证券日报》记者介绍："开工仅半年多，3栋生产车间即将封顶，年内将完成主体建设及首批车间 设备进驻，2026年5月份起将陆续释放产能。" "新基地主要聚焦致根高端原料药项目，该项目将生产舒更葡糖钠、替格瑞洛等尖端品种，同时依托合 成生物学技术革新 ...

股东代理人所持有效表决权股份总数的过半数通过。 情况，出席本次股东大会的关联股东湖南华纳医药投资合伙企业（有限合伙）已 对议案 8、议案 11.02、议案 13、议案 14 回避表决；关联股东徐燕、徐小强已对 议案 8、议案 11.02 回避表决。 三、 律师见证情况 | 证券代码：688799 证券简称：华纳药厂 公告编号：2025-044 | | | | | | | --- | --- | --- | --- | --- | --- | | 湖南华纳大药厂股份有限公司 | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | 一、 会议召开和出席情况 | | | | | | | （一） 股东大会召开的时间：2025 年 5 月 | 12 日 | | | | | | （二） 股东大会召开的地点：湖南省长沙市岳麓区麓天路 | | | 28 号 | ...